Welcome to our dedicated page for Cooper SEC filings (Ticker: COO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CooperCompanies, Inc. (Nasdaq: COO) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its operations as a global medical device company. These SEC filings cover its two business units, CooperVision and CooperSurgical, and include information on revenue, segment performance, margins, cash flow, and significant corporate actions.
On this page, you can review annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which typically present consolidated financial statements, segment data for CooperVision and CooperSurgical, discussions of non‑GAAP measures, and explanations of items such as acquisition and integration‑related charges, business optimization charges, and product line exits. These filings also describe how the company defines and uses metrics like constant currency revenue growth, organic revenue growth, and free cash flow.
Current reports on Form 8‑K provide timely updates on material events, such as quarterly earnings releases, changes in executive responsibilities, and governance developments. For example, recent 8‑K filings have addressed the reporting of quarterly financial results and the assumption of principal accounting officer responsibilities by the company’s Chief Financial Officer. Proxy statements referenced in these filings contain biographical and governance information about directors and senior executives.
Stock Titan enhances access to COO filings by offering AI‑powered summaries that explain key sections of lengthy documents in plain language. Real‑time updates from EDGAR ensure that new 10‑K, 10‑Q, and 8‑K filings appear quickly, while insider transaction reports on Form 4, when available, can be used to monitor trading activity by officers and directors. These tools help users navigate CooperCompanies’ regulatory disclosures more efficiently and understand the financial and governance details that shape the company’s performance.
Cooper Companies reported that officer Holly R. Sheffield, President of CSI, received new equity awards on 12/09/2025. The grants consist of 7,960 Performance Stock Units and 15,921 Restricted Stock Units, each with an exercise price of $0.00 and each linked to an equivalent number of shares of common stock. Following these grants, 7,960 PSUs and 15,921 RSUs are beneficially owned directly.
The PSUs will vest based on The Cooper Companies, Inc. total shareholder return performance relative to an index over a three-year performance period ending October 31, 2028, with between 0% and 200% of the target number eligible to vest and no shares vesting if minimum performance is not achieved. The RSUs vest 25% per year over four years on January 8 of each year beginning on January 8, 2026, and any units that do not vest will be forfeited.
The Cooper Companies reported new equity awards to its EVP & Chief Operating Officer dated 12/09/2025.
The filing shows a grant of 10,508 Performance Stock Units that will vest based on total shareholder return performance relative to an index over a three-year period ending October 31, 2028. Between 0% and 200% of the target PSUs may vest depending on performance, and no shares will vest if minimum TSR performance is not achieved. These PSUs have no expiration date and settle after performance results are certified.
The officer also received 21,016 Restricted Stock Units that vest 25% per year over four years, with a January 8 vesting date beginning on January 8, 2026. This award has no expiration date; the RSUs will either vest or be forfeited. Both awards relate to shares of the company’s common stock and are held directly.
Lawrence E. Kurzius, a director of Cooper Companies, Inc. (COO), reported a purchase of 2,000 shares of the company's common stock on 09/29/2025 at a price of $68.39 per share. After the transaction, he beneficially owned 5,777 shares, held directly. The Form 4 was signed on 09/29/2025 by Kurzius via attorney-in-fact Nicholas Khadder. The filing uses transaction code P indicating a purchase and lists Kurziuss business address in San Ramon, CA.
Albert G. White III, President & CEO and Director of Cooper Companies (COO), reported an insider purchase of 10,000 shares at $68.39 on 09/05/2025, increasing his beneficial ownership to 226,151 shares. The Form 4 was filed individually and signed by an attorney-in-fact on behalf of Mr. White.
Gerard H. Warner III, President of CooperVision and an officer of Cooper Companies (COO), acquired 1,450 shares of Company common stock on 09/05/2025 at $69.23 per share. After the purchase he beneficially owned 18,319 shares. The Form 4 was submitted by a single reporting person and signed by an attorney-in-fact on behalf of Mr. Warner.
Daniel G. McBride, EVP & Chief Operating Officer of The Cooper Companies (COO), reported an open-market purchase of company stock. The Form 4 discloses a purchase of 3,000 shares of Common Stock at a price of $65.04 per share, recorded as a purchase transaction. After this transaction, Mr. McBride directly beneficially owns 63,120 shares and indirectly beneficially owns 94,496 shares through The McBride Family Trust. No derivative securities are reported on this form.
Cooper Companies executive Brian G. Andrews reported an open‑market purchase of 1,525 shares of common stock at a weighted average price of $65.68, acquired indirectly through the Andrews Family Trust where he and his spouse are co‑trustees.
Following this transaction on 09/02/2025, the trust holds 22,191 shares of Cooper Companies, while Andrews directly owns 6,902 shares. His direct holdings include 288 shares previously acquired under the company’s employee stock purchase plan in early 2025.
The Cooper Companies, Inc. reported third-quarter fiscal 2025 results showing continued activity across acquisitions, financing and operations. The company completed acquisitions including obp Surgical for $100.0 million and a fertility company for $33.5 million in 2024, and earlier acquired select Cook Medical assets for $300.0 million (present value $291.6 million). Consolidated gross margin was 65% for the quarter (66% prior-year quarter) driven lower primarily by inventory write-offs related to a product line exit.
Liquidity and capital: working capital was $1,127.7 million versus $928.7 million a year earlier. Total outstanding debt carried an aggregate amount of $2.5 billion; $930.2 million was outstanding on the 2024 Revolving Credit Facility at a weighted-average interest rate of 5.43% and $1,500.0 million remained under the 2021 Term Loan. Share repurchases in the quarter totaled 0.7 million shares for $52.2 million, with $163.6 million remaining authorized. Management disclosed a material weakness in IT general controls impacting CooperSurgical and is implementing remediation steps.
The Cooper Companies, Inc. furnished a current report to disclose that it issued a press release announcing its results for the fiscal third quarter ended July 31, 2025.
The press release, dated August 27, 2025, is provided as Exhibit 99.1 and is incorporated by reference into this report, but is designated as “furnished” rather than “filed” under securities laws. The company also includes an Inline XBRL cover page data file as Exhibit 104.1, and the report is signed by President and Chief Executive Officer Albert G. White III.